Tardive Dyskinesia News and Research

RSS
Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may appear as though the patient is playing an invisible guitar or piano.
Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

BD receives FDA approval for second prefilled injectable drug

BD receives FDA approval for second prefilled injectable drug

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

FDA accepts Sunovion’s two LATUDA sNDAs for review

FDA accepts Sunovion’s two LATUDA sNDAs for review

Antipsychotic drug quandary for Alzheimer’s patients

Antipsychotic drug quandary for Alzheimer’s patients

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

No legal recourse because generic drug caused injury

No legal recourse because generic drug caused injury

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion announces results from LATUDA open-label study for schizophrenia

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Mylan receives final FDA approval for generic Zyprexa ANDA

Mylan receives final FDA approval for generic Zyprexa ANDA

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

Oak Pharmaceuticals acquires three Lundbeck hospital-based injectables

Oak Pharmaceuticals acquires three Lundbeck hospital-based injectables

AstraZeneca settles SEROQUEL XR patent infringement litigation

AstraZeneca settles SEROQUEL XR patent infringement litigation

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia